Search for a clinical trial
Other search option(s)
266 Result(s)
Recruiting trial
= ; Ongoing trial
=
; Terminated trial =
; Funded by an IRDiRC member =
; Member of a ERN =
National clinical trial(s)

WIEN
ADDRESS: NOT PROVIDED - AT


TALAPRO-1: A phase 2, open-label, response rate study of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone) - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

A Phase 2 Study of TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations - AT
Institution: Information not provided - AT

ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE

CUV152: A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum C and V (XPC and XPV) - BE
Institution: Information not provided - BE

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

RecSAMP: Metabotyping of Overweight and Obese Children Towards Early Detection of Insulin Resistance and Low-grade Inflammation by Means of a Rectal Sampler
Universitair Ziekenhuis Brussel
Endocrinologie

VLAAMS BRABANT
LEUVEN


OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - BE
UZ Leuven - Campus Gasthuisberg
Laboratory of Pediatric Immunology

AUVERGNE-RHONE-ALPES
BRON
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III Study
CHU de Lyon HCL - GH Est-Hôpital Femme Mère Enfant
Service de génétique

AUVERGNE-RHONE-ALPES
CLERMONT-FERRAND
PROPLACO-Tel: Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia -FR
CHU de Clermont-Ferrand - Hôpital Gabriel Montpied
CHU Clermont Ferrand

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
PROPHECI: PyROphosPHate Supplementation to Fight ECtopIc Calcification in PseudoXanthoma Elasticum -FR
Institution: Information not provided - FR

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR

Fluconazole as a New Therapeutic Tool in Hypercalciuric Patients With Increased 1,25(OH)2D Levels
Institution: Information not provided - FR

Baden-Württemberg
FREIBURG
SIPA-SOS: An open label phase II study of Sirolismus in patients with segmental overgrowth syndrome
Zentrum für Kinder- und Jugendmedizin Freiburg
Klinik für Pädiatrische Hämatologie und Onkologie

Baden-Württemberg
HEIDELBERG

DOAC-Child: Pharmacokinetics of a microdosed cocktail containing rivaroxaban, apixaban and edoxaban in children with congenital heart defects
Zentrum für Kinder- und Jugendmedizin des Universitätsklinikums Heidelberg
Kinderheilkunde II - Klinik für Kinderkardiologie und angeborene Herzfehler

Bayern
REGENSBURG

Der Einfluss von Timolol Nasenspray auf Epistaxis bei Morbus Osler Patienten
Universitätsklinikum Regensburg
Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde

Berlin
ADDRESS: NOT PROVIDED - DE

Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study -DE-
Institution: Information not provided - DE

Berlin
ADDRESS: NOT PROVIDED - DE

CUV156: A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum (XP)
Institution: Information not provided - DE

Hessen
FRANKFURT AM MAIN


OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study -DE-
Universitätsklinikum Frankfurt
Schwerpunkt Allergologie, Pneumologie und Mukoviszidose

Nordrhein-Westfalen
BONN
EyNeP: Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum (Phase II) - DE
Universitäts-Augenklinik Bonn

LOMBARDIA
PAVIA


Effect of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilatation in patients with Marfan syndrome mutation carriers of the gene FBN1
Fondazione IRCCS Policlinico San Matteo
Laboratorio di Diagnostica Molecolare, Patologia Cardiovascolare e dei Trapianti

LOMBARDIA
PAVIA

Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) (Phase II)- IT
Fondazione IRCCS Policlinico San Matteo
Clinica Medica III

Gelderland
NIJMEGEN
An Uncontrolled, Pilot-study Assessing the Efficacy of Octreotide Long-acting Release to Decrease Transfusion Requirements and Endoscopy Frequency in Patients With Rendu-Osler-Weber and Gastrointestinal Bleeding
Radboudumc - Radboud universitair medisch centrum
Afdeling Maag-, Darm- en Leverziekten

Zuid-Holland
ROTTERDAM

COMPARE 60/80 HBR: Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population
Maasstad Ziekenhuis
Polikliniek Cardiologie

Andalucía
MÁLAGA

Response to oral lansoprazole in inorganic pyrophosphate levels in patients with Grönblad-Stranberg disease (Pseudoxanthoma Elasticum) -ES
Hospital Universitario Virgen de la Victoria
Unidad de Medicina Interna

Cataluña
L'HOSPITALET DE LLOBREGAT

A Randomised, Placebo Controlled, Double Blind, Multicentre Proof of Concept Study to Assess the Safety and Efficacy of Two Doses of VAD044 in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) -ES
Hospital Universitari de Bellvitge
Servicio de Medicina Interna

Madrid
ADDRESS: NOT PROVIDED - ES

EPIK-P2 - A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS) -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum C and V (XPC and XPV) -ES
Institution: Information not provided - ES

Madrid
MADRID


OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - ES
Hospital Universitario La Paz
Servicio de Neurología

Madrid
MADRID

Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multicenter, open-label, rater-blinded Phase II study -ES
Hospital Universitario La Paz
Servicio de Neurología infantil

Suisse Alémanique
BERN
LSCI-NSURG: Intraoperative Laser Speckle Contrast Imaging to Assess Blood Flow During Neurosurgery
Universitätsspital Inselspital
Universitätsklinik für Neurochirurgie

Washington
ADDRESS: NOT PROVIDED - US


A Randomized Double-Blind Controlled Trial of Everolimus in Children and Adolescents With PTEN Mutations (RAD001XUS257T)
Institution: Information not provided - US

SALZBURG
SALZBURG

A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell Carcinoma - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
EB-Haus Austria

SALZBURG
SALZBURG

HOLOGENE17: Prospective, Open-label, Uncontrolled Clinical Trial to Assess the Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified With a Gamma-retroviral (rv) Vector Carrying COL17A1 cDNA for Restoration of Epidermis in Patients With Junctional Epidermolysis Bullosa (Phase 1-2)
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
EB-Haus Austria

SALZBURG
SALZBURG

HOLOGENE7: Prospective, Open-label, Uncontrolled Clinical Trial to Assess the Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified With a Gamma-retroviral (rv) Vector Carrying COL7A1 cDNA for Restoration of Epidermis in Patients With Recessive Dystrophic Epidermolysis Bullosa (Phase 1-2) - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
EB-Haus Austria

SALZBURG
SALZBURG
An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-EB on Epidermolysis Bullosa (EB) - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
EB-Haus Austria

WIEN
ADDRESS: NOT PROVIDED - AT
REFLECT: A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB) - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT
Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

REAL 8: A Study Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® as Well as Evaluating Long-term Safety of Somapacitan in a Basket Study Design in Children With Short Stature Either Born Small for Gestational Age or With Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature - AT
Institution: Information not provided - AT

ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
MERGE - MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study - BE
Institution: Information not provided - BE

ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
PREVEnt: A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE) - BE
Institution: Information not provided - BE

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

RISE/MRX-801: Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service de gastro-entérologie et hépatologie pédiatrique

Québec
ADDRESS: NOT PROVIDED - CA
MOVE Trial: A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) -GB
Institution: Information not provided - CA

Québec
ADDRESS: NOT PROVIDED - CA

EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS) - CA
Institution: Information not provided - CA

Québec
ADDRESS: NOT PROVIDED - CA
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -CA
Institution: Information not provided - CA

Finland
HELSINKI
Immunodeficiency in cartilage-hair hypoplasia: sub-project on safety of vaccination against chickenpox -FI
HUS - Helsinki University Hospital
New Children's Hospital

AUVERGNE-RHONE-ALPES
LYON
VETCOSED: Effectiveness of Wearing a Compression Garment (SED CICATREX® Model) for Patients With Hypermobility Type of Ehlers-Danlos Syndrome
Centre Médico-Chirurgical de Réadaptation des Massues - Croix-Rouge française
Médecine physique et réadaptation Adultes

BOURGOGNE-FRANCHE-COMTE
DIJON
SESAM: A Phase II Double-blind Multi-center, Placebo-controlled Trial, to Assess the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP) -FR
CHU Dijon Bourgogne - Hôpital François Mitterrand
Centre Hospitalier Universitaire Dijon

GRAND-EST
VANDOEUVRE-LÈS-NANCY

NOVASED: Efficiency Clinical Study of NOVATEX MEDICAL Compression Garments in Patients With Ehlers-Danlos Syndrome.
CHU de Nancy - Hôpitaux de Brabois
Service de médecine interne et immunologie clinique

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
MERGE - MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study - FR
Institution: Information not provided - FR

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR

RISE: Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome. - Maralixibat Infant Safety Evaluation -FR
Institution: Information not provided - FR

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR

EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA-Related Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (EPIK-P1) - FR
Institution: Information not provided - FR

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -FR
Institution: Information not provided - FR

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome -FR
Institution: Information not provided - FR

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
PREVEnt: A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE) -FR
Institution: Information not provided - FR

ILE-DE-FRANCE
PARIS

ARCADE: Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial (Phase III) - FR
AP-HP. Centre - Université de Paris - HEGP Hôpital Européen Georges Pompidou
Service de génétique - CR des Maladies Vasculaires Rares

ILE-DE-FRANCE
PARIS

MABUL : A Comparative Study of the Healing of Chronic Skin Ulcers of Recessive Dystrophic Epidermolysis Bullosa : Standard Dressing Versus Amniotic Membrane (Phase III)
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service de dermatologie

ILE-DE-FRANCE
PARIS

EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS) - FR
Hôpital Necker-Enfants Malades
Néphropathies héréditaires et rein en développement

ILE-DE-FRANCE
PARIS

FancoMob : Pilot Study Assessing the Feasibility of CD34+ Cells Mobilization and Collection After Treatment With G-CSF and Plerixafor in Patients With Fanconi Anemia for Subsequent Treatment by Gene Therapy (Phase I-II)
Hôpital Necker-Enfants Malades
Service d'Hématologie adulte

ILE-DE-FRANCE
PARIS
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARy-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) (Phase II) - FR
Hôpital Necker-Enfants Malades
Service de Génétique Moléculaire

ILE-DE-FRANCE
PARIS

A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARy Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) - FR
Hôpital Necker-Enfants Malades
Service de Génétique Moléculaire

ILE-DE-FRANCE
PARIS
A Phase 2, Open-Label, Efficacy and Safety Study of an RARy Specific Agonist (Palovarotene) to Prevent Heterotopic Ossification in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Hôpital Necker-Enfants Malades
Service de Génétique Moléculaire

ILE-DE-FRANCE
PARIS

ACTHYF: Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children - FR
Institut Jérôme Lejeune

OCCITANIE
TOULOUSE

OXYJEUNE : Effects of Intranasal Administrations of Oxytocin on Behavioural Troubles, Hyperphagia and Social Skills in Children With Prader-Willi Syndrome Aged From 3 to 12 Years (Phase III)
CHU de Toulouse - Hôpital des Enfants
Centre de référence du syndrome de Prader-Willi

OCCITANIE
TOULOUSE

Long-term Interventional Follow-up Study up to 4 Years of Age of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial and Comparison With an Untreated Cohort of Children With Prader-Willi Syndrome -FR
CHU de Toulouse - Hôpital des Enfants
Centre de référence du syndrome de Prader-Willi

Bayern
GARMISCH-PARTENKIRCHEN

STOPFOP: Saracatinib Trial TO Prevent FOP. A 6-month double blind randomized controlled trial of AZD0530 versus placebo, followed by a 12 month open label extension phase -DE
Klinikum Garmisch-Partenkirchen GmbH
Abteilung für Kinder- & Jugendmedizin

Bayern
MÜNCHEN


SynCoRAS: Improvement of Synaptic Plasticity and Cognitive Function in RAS Pathway Disorders (GeNeRARe study)
TUM Fakultät für Medizin

Bayern
MÜNCHEN


SynCoRAS: Improvement of Synaptic Plasticity and Cognitive Function in RAS Pathway Disorders (GeNeRARe study)
kbo-Kinderzentrum München gemeinnützige GmbH
kbo-Kinderzentrum München

Berlin
ADDRESS: NOT PROVIDED - DE
MOVE TRIAL: A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) -DE-
Institution: Information not provided - DE

Berlin
ADDRESS: NOT PROVIDED - DE

EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS) - DE
Institution: Information not provided - DE

Berlin
ADDRESS: NOT PROVIDED - DE
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -DE
Institution: Information not provided - DE

County Dublin
ADDRESS: NOT PROVIDED - IE

EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA-Related Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (EPIK-P1) - IE
Institution: Information not provided - IE

EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Open-label study to evaluate the efficacy and tolerability of orally administered rosiglitazone in patients with progressive bone Fibrodysplasia (FOP)
Institution: Information not provided - IT

EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR alfa-beta+ T cells in pediatric patients affected by hematological disorders - IT
Institution: Information not provided - IT

EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome - IT
Institution: Information not provided - IT

LIGURIA
GENOVA


A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602) - IT
Ospedali Galliera
S.S.D. Microcitemia, anemie congenite e dismetabolismo del ferro

LOMBARDIA
MILANO
An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa (phase III) - IT
IRCCS Ca' Granda Ospedale Maggiore Policlinico - Padiglione De Marchi
U.O.S. di Infettivologia Pediatrica

PIEMONTE
TORINO

EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS) - IT
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Regina Margherita
Genetica Clinica Pediatrica

SICILIA
MESSINA

Randomized, Placebo-controlled, Cross-over, Double-blind Study of a Metabolic Support Therapy With Q10 Ubiquinol and a Multivitamin B and E Complex in Two Cohorts of Patients With Idiopathic and Syndromic Autism (Phelan-McDermid Syndrome)
Università degli Studi di Messina

JAPAN
ADDRESS : NOT PROVIDED - JP

Multicenter randomized double-blind comparison test followed by open-label continuous administration test of NPC-12T for Fibrodysplasia Ossificans Progressiva
Institution: Information not provided - JP

Utrecht
ADDRESS: NOT PROVIDED - NL

EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS) - NL
Institution: Information not provided - NL

Utrecht
UTRECHT
Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa (phase II)
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie

Zuid-Holland
ROTTERDAM

Dutch Growth Hormone Cohort study in children with Prader-Willi syndrome: Long-term effects on growth, body composition, activity level and psychosocial development
Stichting Kind en Groei

Zuid-Holland
ROTTERDAM
N- acetylcysteine treatment for skin picking in children and young adults with PWS: a randomized, controlled, cross-over trial
Stichting Kind en Groei

Østlandet
ADDRESS: NOT PROVIDED - NO

EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS) - NO
Institution: Information not provided - NO

Comunidad Valenciana
VALENCIA

PIVOINE: Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged >=14 Years with Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 [...] -ES
Hospital Universitario y Politécnico La Fe

Madrid
ADDRESS: NOT PROVIDED - ES
SOLO-1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

FANCOLEN-II: A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype A -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

FALKON: A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of 2 dosage regimens of oral IPN60130 for the treatment of fibrodysplasia ossificans progressiva in male and female participants 5 years of age and older - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA-Related Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (EPIK-P1) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) in patients with Fanconi Anaemia Subtype A - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

Progress: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva -ES
Institution: Information not provided - ES

Madrid
MADRID
A Phase 3 Multi-Center, One-Year, Open-Label study of Setmelanotide in Pediatric Patients Aged 2 to <6 years of age with Rare Genetic Causes of Obesity -ES
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo

Madrid
MADRID
An open clinical trial, phase II to evaluate the efficacy and safety of the use of eltrombopag in children and adolescents with Fanconi Anemia -ES
Hospital Infantil Universitario Niño Jesús
Servicio de Hematología y Hemoterapia

Madrid
MADRID
MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study - ES
Hospital Universitario La Paz

Region Stockholm
ADDRESS: NOT PROVIDED - SE
MOVE Trial: A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) - SE
Institution: Information not provided - SE

Suisse Romande
ADDRESS: NOT PROVIDED - CH

EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS) - CH
Institution: Information not provided - CH

Greater London
ADDRESS: NOT PROVIDED - GB

EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS) - GB
Institution: Information not provided - GB

Greater London
ADDRESS: NOT PROVIDED - GB
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -CA
Institution: Information not provided - GB

Greater London
ADDRESS: NOT PROVIDED - GB
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -GB
Institution: Information not provided - GB

Greater London
ADDRESS: NOT PROVIDED - GB
PREVEnt: A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE) -GB
Institution: Information not provided - GB

Greater London
LONDON
Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust
Great Ormond Street Hospital

Greater London
LONDON
A prospective placebo controlled phase II study to evaluate the use of allogeneic fibroblasts for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa
Guy's Hospital
Clinical Research Facilities

Greater London
LONDON

EBSTEM: A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa
Guy's Hospital
Clinical Research Facilities

Merseyside
LIVERPOOL
Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome
Fazakerley Hospital
University Hospital Aintree - Diabetes and Endocrinology

West Midlands
BIRMINGHAM

Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
University Hospital Birmingham
Marshfield Clinic

Colorado
ENGLEWOOD

Illinois
CHICAGO

An Open Label Extension, Multi-Center, Study to Evaluate the Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa (Terminated) - US
Children's Hospital of Chicago

Massachusetts
BOSTON

A Randomized Phase 2 Study of Vincristine Versus Sirolimus to Treat High Risk Kaposiform Hemangioendothelioma (KHE) - US
Boston Children's Hospital

Ohio
CINCINNATI


Quercetin in Children With Fanconi Anemia; a Pilot Study (Phase 1) - US
Cincinnati Children's Hospital Medical Center
Department of Pediatry

Washington
ADDRESS: NOT PROVIDED - US


Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US


A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US


Phase 1 Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US


Evaluating the Neurophysiologic and Clinical Effects of Single-Dose Acamprosate, Lovastatin, Minocycline and Placebo in Fragile X Syndrome
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US


Effects of AFQ056 on Language Learning in Young Children With Fragile X Syndrome (FXS)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US

A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US


Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
Institution: Information not provided - US

WIEN
ADDRESS: NOT PROVIDED - AT
ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 12 Months in Prepubertal Children With Achondroplasia - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

CAHtalyst: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment (Phase 3) - AT
Institution: Information not provided - AT

ANTWERPEN
ANTWERPEN-EDEGEM


MCDS-Therapy: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children - BE
Centrum Medische Genetica - UZA
Centrum Medische Genetica - Het Universitair Ziekenhuis Antwerpen

ANTWERPEN
ANTWERPEN-EDEGEM


A phase 2 multiple dose, randomized study to assess the safety, tolerability, pharmacokinetics and efficacy of recifercept in children with achondroplasia - BE
Centrum Medische Genetica - UZA
Centrum Medische Genetica - Het Universitair Ziekenhuis Antwerpen

ANTWERPEN
EDEGEM (ANTWERPEN)
Efficacy and Safety of a 4 Year Combination Therapy of Growth Hormone and Gonadotropin- Releasing Hormone Agonist in Children With a Short Predicted Height
Antwerp University Hospital - UZA
Kindergeneeskunde/Pediatrics

OOST-VLAANDEREN
GENT

Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway - BE
Ghent University Hospital - UZ Gent
Ghent University Hospital

Baden-Württemberg
FREIBURG

MCDS-Therapy: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children - DE
Zentrum für Kinder- und Jugendmedizin Freiburg
Sektion Pädiatrische Genetik der Klinik für Allgemeine Kinder- und Jugendmedizin

Bayern
ERLANGEN
ECP-002e: Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002 - DE
Kinder- und Jugendklinik des Universitätsklinikums Erlangen
Abteilung für Molekulare Pädiatrie

County Dublin
ADDRESS: NOT PROVIDED - IE

TOPAZ - Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid-IE
Institution: Information not provided - IE

EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT

A phase 2 multiple dose, randomized study to assess the safety, tolerability, pharmacokinetics and efficacy of recifercept in children with achondroplasia - IT
Institution: Information not provided - IT

JAPAN
ADDRESS : NOT PROVIDED - JP


Pilot study of topical medicine of rapamycin for large diffuse plexiform neurofibroma of neurofibromatosis type 1
Institution: Information not provided - JP

Zuid-Holland
ROTTERDAM


NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie

Zuid-Holland
ROTTERDAM


NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Neurowetenschappen

Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 12 Months in Prepubertal Children With Achondroplasia -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

CAHtalyst: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES


An open-label, multicenter study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7248824 in participants with Angelman syndrome -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES


A phase 2 multiple dose, randomized study to assess the safety, tolerability, pharmacokinetics and efficacy of recifercept in children with achondroplasia -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A multi-center, open-label, single-arm Phase I dose-escalation and Phase II dose-expansion study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of FCN-159 in adult and pediatric participants with neurofibromatosis type 1 - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

CAHtalyst Pediatric Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

PROPEL 2: Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

PROPEL OLE: Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES


A phase II, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, efficacy, and pharmacodynamics of 52 weeks of treatment with basmisanil in children with dup15q syndrome -ES
Institution: Information not provided - ES

Murcia
EL PALMAR
EDELIFE: A prospective, open-label, genotype-match controlled, multicenter clinical trial to investigate the efficacy and safety of intra-amniotic ER004 as a prenatal treatment for male subjects with X-linked hypohidrotic ectodermal dysplasia (XLHED) - ES
Hospital Clínico Universitario Virgen de la Arrixaca

País Vasco
VITORIA-GASTEIZ


A phase 2 open label extension study to assess the long-term safety, tolerability, pharmacokinetics and efficacy of recifercept in children with achondroplasia - ES
Hospital Vithas Vitoria - Hospital Vithas San José
Unidad de Cirugía Artroscópica

Region Skåne
LUND

plexifpc - Treatment of NF1-related Plexiform Neurofibroma With Trametinib; a Single Arm, Open-label Trial With the Goals of Volumetric Partial Remission and Pain Relief - SE
Skånes Universitetssjukhus
Skåne University Hospital

Region Stockholm
SOLNA

BOOSTB4: An Exploratory, Open Label, Multiple Dose, Multicentre Phase I/II Trial Evaluating Safety and Efficacy of Postnatal or Prenatal and Postnatal Intravenous Administration of Allogeneic Expanded Fetal Mesenchymal Stem Cells for the Treatment of Severe Osteogenesis Imperfecta Compared With a Combination of Historical and Untreated Prospective Controls - SE
Astrid Lindgrens Barnsjukhus
Astrid Lindgren Children's Hospital

Edinburgh
EDINBURGH

TOPAZ - Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid
University of Edinburgh
Edinburgh Clinical Trials Unit

Greater London
LONDON

A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma
GOSH NHS Foundatin Trust
Great Ormond Street Hospital

Tyne & Wear
NEWCASTLE UPON TYNE

MCDS-Therapy: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children-GB
Freeman Hospital, The newcastle upon Tyne Hospitals NHS Foundation Trust
The Newcastle upon Tyne Hospitals NHS Foundation Trust

New Jersey
SOUTH PLAINFIELD


STAR: A Phase 2, Multicenter, Randomized, Double Masked, Placebo Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia - US
PTC Therapeutics Inc.

Texas
DALLAS

A Phase 1 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency - US
University of Texas Southwestern Medical Center

Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia -GB
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US


Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US


Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Institution: Information not provided - US

Victoria
ADDRESS: NOT PROVIDED - AU

COMPASS: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II -AU
Institution: Information not provided - AU

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

COMPASS: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II - BE
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc

OOST-VLAANDEREN
GENT
An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset POMC Deficiency Obesity due to Bi-Allelic Loss-of-Function POMC or PCSK1 Genetic Mutation - BE
Ghent University Hospital - UZ Gent
Ghent University Hospital

OOST-VLAANDEREN
GENT
ONYX: An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab - BE
Ghent University Hospital - UZ Gent
NMRC UZ Gent

AUVERGNE-RHONE-ALPES
BRON
IMPROVES: A Phase IIa Study to Investigate Safety, Pharmacokinetics, and Efficacy of Odiparcil in Patients 16 Years and Above With Mucopolysaccharidosis (MPS) Type VI - FR
CHU de Lyon HCL - GH Est-Hôpital Femme Mère Enfant
Service d'endocrinologie et de diabétologie pédiatriques et maladies héréditaires du métabolisme

AUVERGNE-RHONE-ALPES
BRON

TREATMENT OF FIBROUS DYSPLASIA OF BONE WITH TOCILIZUMAB AMONG PATIENTS WHO DO NOT RESPOND TO BISPHOSPHONATES. THE TOCIDYS TRIAL (Phase II) - FR
Hospices Civils de Lyon - Groupement Hospitalier EST
Service de rhumatologie et de pathologie osseuse

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR

COMPASS: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II -FR
Institution: Information not provided - FR

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
ONYX: An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab -FR
Institution: Information not provided - FR

Baden-Württemberg
ULM

An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity Due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation -DE-
Zentrum für Seltene Erkrankungen am Universitätsklinikum Ulm
Zentrum für Seltene Erkrankungen (ZSE) ULM

Berlin
ADDRESS: NOT PROVIDED - DE

COMPASS: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II - DE
Institution: Information not provided - DE

Berlin
ADDRESS: NOT PROVIDED - DE
ONYX: An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab -DE
Institution: Information not provided - DE

Hamburg
HAMBURG


COMPASS: CNS Unmet Medical Need in Mucopolysaccharidosis: A Phase 2 Safety and Pharmacokinetics Study of Ataluren - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Klinik und Poliklinik für Kinder- und Jugendmedizin

Rheinland-Pfalz
MAINZ


A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients With Mucopolysaccharidosis type 2 Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age - DE
Universitätsmedizin Mainz
Villa Metabolica - Schwerpunktbereich angeborene Stoffwechselerkrankungen

Rheinland-Pfalz
MAINZ
IMPROVES: A Phase IIa Study to Investigate Safety, Pharmacokinetics, and Efficacy of Odiparcil in Patients 16 Years and Above With Mucopolysaccharidosis (MPS) Type VI - DE
Universitätsmedizin Mainz
Villa Metabolica - Schwerpunktbereich angeborene Stoffwechselerkrankungen

CAMPANIA
NAPOLI


A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects With Mucopolysaccharidosis Type VI (MPS VI) Using Adeno-Associated Viral Vector 8 to Deliver the Human ARSB Gene to Liver
TIGEM - Telethon Institute of Genetics and Medicine
Laboratorio di Ricerca

LAZIO
ROMA
ONYX: An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab - IT
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Centro Clinico Nemo Pediatrico

Cataluña
ESPLUGUES DE LLOBREGAT

A Phase III study of JR-141 in Mucopolysaccharidosis type II (Hunter Syndrome) patients -ES
Hospital Sant Joan de Déu Barcelona

Madrid
ADDRESS: NOT PROVIDED - ES

An Open-label, Ascending Multiple-dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

COMPASS: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II -ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
ONYX: An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab -ES
Institution: Information not provided - ES

Madrid
MADRID

Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway -ES
Hospital Infantil Universitario Niño Jesús

Madrid
MADRID

An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase® in Patients with Hunter Syndrome and Cognitive Impairment -ES
Hospital Infantil Universitario Niño Jesús
Servicio de Neurología

Region Stockholm
ADDRESS: NOT PROVIDED - SE

COMPASS: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II - SE
Institution: Information not provided - SE

Greater London
ADDRESS: NOT PROVIDED - GB

COMPASS: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II -GB
Institution: Information not provided - GB

Greater London
LONDON
MCRN007: An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome (phase II)
University College London Hospitals, NHS Foundation Trust
Endocrinology Department

Oxfordshire
OXFORD
A Phase 2b Study, Multicentre, Multinational, Placebo-controlled, Double-blind, Dose-finding Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804-GB
Nuffield Orthopaedic Centre
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences

West Midlands
BIRMINGHAM

MCRN174 (HGT-HIT-046) : An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction with Intravenous Elaprase in Pediatric Patients with Hunter Syndrome and Cognitive Impairment (Phase I/II)
Birmingham Children's Hospital NHS Foundation Trust
Birmingham Children's Hospital

Maryland
BALTIMORE


Study of Growth Hormone Use in Patients With Pseudohypoparathyroidism Type 1a (Subtype of Albright Hereditary Osteodystrophy) (Phase 2/3) - US
Kennedy Krieger Institute

Washington
ADDRESS: NOT PROVIDED - US

A Long-Term, Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects with MPS 7
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US

An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less than 5 years old
Institution: Information not provided - US

OBERÖSTERREICH
LINZ

A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH) - AT
Kepler Universitätsklinikum - Med Campus IV.
Universitätsklinik für Kinder- und Jugendheilkunde

Québec
MONTRÉAL
MOR-008: A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) Phase II. CA
Glen / McGill Univeristy Health Centre - Centre Universitaire de santé McGill
Medical Genetics - Génétique Médicale

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR

12-months of Treatment With Burosumab in Children and Adolescents With X-linked Hypophosphatemia: a Prospective Longitudinal Cohort Study
Institution: Information not provided - FR

ILE-DE-FRANCE
LE KREMLIN-BICÊTRE

A phase I/II, open label study of intracerebral administration of adeno-associated viral vector containing the human alpha-N-acetylglucosaminidase (NAGLU) cDNA in children with Sanfilippo type B syndrome - FR
APHP. Université Paris-Saclay, Hôpital Bicêtre
Service de Neuropédiatrie

Bayern
WÜRZBURG

BurGER: An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With X linked Hypophosphatemia (XLH) in GERmany
Lehrstuhl für Orthopädie der Universität Würzburg
Bernhard-Heine-Centrum für Bewegungsforschung

Hamburg
HAMBURG

A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Intracerebroventricular BMN 250 in Patients With Mucopolysaccharidosis type 3B (Sanfilippo syndrome type B) - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Klinik und Poliklinik für Kinder- und Jugendmedizin

Hamburg
HAMBURG


An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis type 3A Disease (Phase II) - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Klinik und Poliklinik für Kinder- und Jugendmedizin

Hamburg
HAMBURG

An open, non-controlled, parallel, ascending multiple-dose, multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SOBI003 in pediatric MPS IIIA patients -DE-
UKE - Universitätsklinikum Hamburg-Eppendorf
Klinik und Poliklinik für Kinder- und Jugendmedizin

Hamburg
HAMBURG

AAVance: An Open-Label, Single-Arm, Multicenter Study of Intracerebral Administration of Adeno-Associated Viral Vectors Serotype rh10 Carrying the Human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA for the Treatment of Mucopolysaccharidosis Type IIIA -DE-
UKE - Universitätsklinikum Hamburg-Eppendorf
Klinik und Poliklinik für Kinder- und Jugendmedizin

Hamburg
HAMBURG
Open-Label Multicenter Extension Study to Further Evaluate Safety, Tolerability and Efficacy of Intracerebroventricular AX 250 Treatment in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B) Patients - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Klinik und Poliklinik für Kinder- und Jugendmedizin

County Dublin
ADDRESS: NOT PROVIDED - IE
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH)-IE
Institution: Information not provided - IE

Noord-Holland
AMSTERDAM

An Open-Label Extension of Study HGT-SAN-055 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA) (Phase I-II) - NL
Amsterdam UMC, locatie AMC
Polikliniek Kindermetabole Ziekten

Noord-Holland
AMSTERDAM

An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease (Phase II) - NL
Amsterdam UMC, locatie AMC
Polikliniek Kindermetabole Ziekten

Andalucía
SEVILLA

A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH) - ES
Hospital Universitario Virgen del Rocío
Unidad de Nefrología Pediátrica

Cataluña
ESPLUGUES DE LLOBREGAT
Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients with MPSIIIA - ES
Hospital Sant Joan de Déu Barcelona
Servicio de Neurología

Galicia
SANTIAGO DE COMPOSTELA

A Long-term Follow-up Study of Patients with MPS IIIA from Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH) - ES
Complejo Hospitalario Universitario de Santiago

Galicia
SANTIAGO DE COMPOSTELA
Phase I/II Gene Therapy Clinical Trial of scAAV9.U1A.SGSH for Mucopolysaccharidosis IIIA -ES
Complejo Hospitalario Universitario de Santiago
Servicio de Pediatría

Greater Manchester
ADDRESS: NOT PROVIDED - UK

AAVance: An Open-Label, Single-Arm, Multicenter Study of Intracerebral Administration of Adeno-Associated Viral Vectors Serotype rh10 Carrying the Human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA for the Treatment of Mucopolysaccharidosis Type IIIA-GB
Institution: Information not provided - UK

Washington
ADDRESS: NOT PROVIDED - US

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Institution: Information not provided - US
Multinational clinical trial(s)

County Dublin
ADDRESS: NOT PROVIDED - IE
CUV152: A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients With Xeroderma Pigmentosum C and V (XPC and XPV).
Institution: Information not provided - IE

EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study
Institution: Information not provided - IT

JAPAN
ADDRESS : NOT PROVIDED - JP
A confirmatory clinical study to evaluate efficacy and safety of ISN001 in patients with epidermolysis bullosa
Institution: Information not provided - JP

Suisse Romande
ADDRESS: NOT PROVIDED - CH
A randomized, double-blinded, regimen controlled, phase II, multicenter study to assess the efficacy and safety of two different Vismodegib regimens in patients with multiple Basal Cell Carcinoma
Institution: Information not provided - CH

Washington
ADDRESS: NOT PROVIDED - US
Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multi-center, open-label, rater-blinded Phase II study - IB1001-203
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
EPIK-P2: A Phase II Double-blind Study With an Upfront, 16-week Randomized, Placebo-controlled Period, to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals With PseudoXanthoma Elasticum.
Institution: Information not provided - US

Québec
ADDRESS: NOT PROVIDED - CA
MOVE Trial: A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Institution: Information not provided - CA

ILE-DE-FRANCE
PARIS
GENEGRAFT: Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (Orphan drug designation (EU/3/09/630))
Hôpital Necker-Enfants Malades
Service de dermatologie

Baden-Württemberg
FREIBURG
REFLECT: A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB)
Universitätsklinikum Freiburg

Dél-Dunántúl
ADDRESS: NOT PROVIDED - HU
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome.
Institution: Information not provided - HU

Utrecht
ADDRESS: NOT PROVIDED - NL
STOPFOP: Saracatinib Trial TO Prevent FOP
Institution: Information not provided - NL

Utrecht
ADDRESS: NOT PROVIDED - NL
Global Growth Hormone Study in Adults With Prader-Willi Syndroom
Institution: Information not provided - NL

Region Stockholm
ADDRESS: NOT PROVIDED - SE
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy
Institution: Information not provided - SE

Suisse Romande
ADDRESS: NOT PROVIDED - CH
Sequential, Two-period Study to Assess the Pharmacokinetics, Safety & Tolerability of Single and Multiple Oral Doses of AFQ056 in Patients With FXS (Fragile X Syndrome) Aged 5-11 Years (Cohort 1) and 3-4 Years (Cohort 2) (Phase I) (Coordination)
Institution: Information not provided - CH

Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label Study to Evaluate the Long-term Safety and Tolerability of AFQ056 in Adolescent Patients With Fragile X Syndrome (Phase II-III) (Coordination)
Institution: Information not provided - CH

Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of AFQ056 in Adolescent Patients With Fragile X Syndrome (Phase II-III) (Coordination)
Institution: Information not provided - CH

Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label Study to Evaluate the Long-term Safety, Tolerability and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome (Phase II) (Coordination)
Institution: Information not provided - CH

Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome (Phase II) (Coordination)
Institution: Information not provided - CH

Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome (Phase II) (Coordination)
Institution: Information not provided - CH

Suisse Romande
ADDRESS: NOT PROVIDED - CH
EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA-Related Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (EPIK-P1)
Institution: Information not provided - CH

Greater London
LONDON
ZEPHYR: A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP-531), an Unacylated Ghrelin Analog, on Food-related Behaviors in Patients With Prader-Willi Syndrome
Millendo Therapeutics Ltd

California
FOSTER CITY
MERGE - MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
Mirum Pharmaceuticals, Inc.

North Carolina
DURHAM

Texas
HOUSTON
Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.

Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
An Open Label, Multi-center, Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients with Epidermolysis Bullosa (Phase III)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
RISE: Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome. - Maralixibat Infant Safety Evaluation.
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
Phase III Clinical Trial for the Treatment of Myeloid Leukemia in Children with Down Syndrome 2018 - ML-DS 2018
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
An Open-Label, Multicenter Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation.
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
PREVEnt: A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE).
Institution: Information not provided - US

Victoria
ADDRESS: NOT PROVIDED - AU
A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas
Institution: Information not provided - AU

Québec
ADDRESS: NOT PROVIDED - CA
TAM4MTM: A Phase 1/2 Randomized, Placebo-Controlled, Double-Blinded, Single Crossover Study to Determine the Safety and Efficacy of Tamoxifen Therapy for Myotubular Myopathy (XLMTM)
Institution: Information not provided - CA

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial
Institution: Information not provided - FR

Region Stockholm
ADDRESS: NOT PROVIDED - SE
BOOSTB4: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls.
Institution: Information not provided - SE

Suisse Romande
ADDRESS: NOT PROVIDED - CH
A randomized, open label intra-patient dose escalation study with an untreated reference group to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of multiple infusions of BPS804 in adults with moderate osteogenesis imperfecta
Institution: Information not provided - CH

Greater London
ADDRESS: NOT PROVIDED - GB
A Phase III study of efficacy, safety and tolerability of Chronocort® compared with standard glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia.
Institution: Information not provided - GB

Greater Manchester
RADCLIFFE

Tyne & Wear
NEWCASTLE UPON TYNE
MCDS-Therapy: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children
Newcastle University
Institute of Genetic Medicine

Massachusetts
CAMBRIDGE
ECP-002: A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Edimer Pharmaceuticals Inc.

Washington
ADDRESS: NOT PROVIDED - US
An open-label, multicenter, multinational study of the safety, efficacy and pharmacokinetics of ENB-0040 (asfotase alfa : human recombinant tissue nonspecific alkaline phosphatase fusion protein) in infants and children under 5 years of age with hypophosphatasia (HPP) (Phase II/III)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A phase 2 multiple dose, randomized study to assess the safety, tolerability, pharmacokinetics and efficacy of recifercept in children with achondroplasia.
Institution: Information not provided - US

WIEN
ADDRESS: NOT PROVIDED - AT
Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases
Institution: Information not provided - AT

EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects with Mucopolysaccharidosis type VI (MPS VI) Using Adeno-Associated Viral Vector 8 to Deliver the human ARSB gene to Liver.
Institution: Information not provided - IT

Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase 2b Study, Multicentre, Multinational, Placebo-controlled, Double-blind, Dose-finding Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Institution: Information not provided - CH

Washington
ADDRESS: NOT PROVIDED - US
A Controlled, Randomized, Two-arm, Open-label, Assessor-blinded, Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Elaprase® in Pediatric Patients with Hunter Syndrome and Early Cognitive Impairment (Phase II-III)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity Due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
COMPASS: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II.
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
ONYX: An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab.
Institution: Information not provided - US

HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
AAVance: An Open-Label, Single-Arm, Multicenter Study of Intracerebral Administration of Adeno-Associated Viral Vectors Serotype rh10 Carrying the Human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA for the Treatment of Mucopolysaccharidosis Type IIIA.
Institution: Information not provided - FR

Region Stockholm
ADDRESS: NOT PROVIDED - SE
An open, non-controlled, parallel, ascending multiple-dose, multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SOBI003 in pediatric MPS IIIA patients
Institution: Information not provided - SE

Washington
ADDRESS: NOT PROVIDED - US
A Phase III, Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in patients with Mucopolysaccharidosis type 4A (Morquio disease type A)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
An Open-Label Extension of Study HGT-SAN-055 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA) (Phase I-II)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A phase 2, open-label, multinational clinical study to evaluate the safety and efficacy of BMN 110 in pediatric patients less than 5 years of age with mucoplysaccaridosis IVA (Morquio A syndrome)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) (MOR-008)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
MOR-006: A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Controlled, Open-label, Multicenter, Phase IIb Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration via an Intrathecal Drug Delivery Device in Pediatric Patients with Early Stage Mucopolysaccharidosis Type III A Disease
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease (Phase II)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH)
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US